Claims for Patent: 8,114,582

Summary for Patent: 8,114,582

Title:	Fluorescence polarization instruments and methods for detection of exposure to biological materials by fluorescence polarization immunoassay of saliva, oral or bodily fluids
Abstract:	The inventive subject matter relates to a method for detecting the presence of a biological substance of interest in a test sample of saliva or oral fluid, comprising combining said test sample with a fluorescence-labeled ligand to said biological substance and detecting a change in the fluorescence polarization of said test sample produced by binding of said fluorescence-labeled ligand to said biological substance. In one aspect of the inventive subject matter, said method comprises additional steps for comparing the fluorescence polarization of said test sample with the fluorescence polarization of a control solution. Also provided is a miniaturized, portable apparatus for measuring the fluorescence polarization of a liquid sample.
Inventor(s):	Cullum; Malford E. (Grayslake, IL), Simonson; Lloyd G. (Spring Grove, IL), Schade; Sylvia Z. (Riverside, IL), Lininger; Linda A. (Grayslake, IL), McArthur; Alan L. (Mokena, IL)
Assignee:	The United States of America as represented by the Secretary of the Navy (Washington, DC)
Application Number:	12/163,412
Patent Claims:	1. A method for detecting the presence of antibodies Bacillus anthracis or Mycobacterium tuberculosis in a test sample, comprising the steps of: (a) collecting a test sample selected from the group consisting of saliva, oral fluid and a bodily fluid from a subject, (b) combining said test sample with a fluorescence-labeled ligand to said-antibodies to produce an assay solution, and (c) measuring the change in fluorescence polarization of said assay solution. 2. The method of claim 1, wherein said method comprises the additional steps of: (a) measuring the fluorescence polarization of a negative control solution of said fluorescence-labeled ligand, a positive control solution of said fluorescence-labeled ligand bound to a known target molecule of said ligand, or both, and (b) comparing the measured fluorescence polarization of said assay solution with the measured fluorescence polarization of said negative control solution, said positive control solution, or both. 3. The method of claim 1, further comprising the steps of: (a) measuring the background fluorescence polarization reading of said test sample; and (b) measuring the change in the fluorescence polarization of said assay solution. 4. The method of claim 1, wherein said fluorescence-labeled ligand is selected from the group consisting of an antigen, an antibody, a receptor, and an inhibitor, wherein said ligand is capable of specifically binding to said antibody. 5. The method of claim 4, wherein said antigen is selected from the group consisting of a ligand to a monoclonal antibody, a ligand to a polyclonal antibody, a ligand to a chimeric antibody, a ligand to a Fab antibody fragment, and a ligand to a (Fab)2 antibody fragment. 6. The method of claim 1, wherein said antibody to Bacillus anthracis is a monoclonal antibody to Bacillus anthracis protective antigen protein. 7. The method of claim 1, wherein said antibody to Mycobacterium tuberculosis is selected from the group consisting of CFP-10, ESAT-6, and MPT-63. 8. The method of claim 1, wherein said fluorescence-labeled ligand has a molecular weight less than about 30,000 Daltons. 9. The method of claim 1, wherein said fluorescence-labeled ligand has a molecular weight less than about 20,000 Daltons. 10. The method of claim 1, wherein said fluorescence-labeled ligand has a molecular weight less than about 10,000 Daltons. 11. The method of claim 1, wherein said fluorescence-labeled ligand comprises a fluorochrome selected from the group consisting of 7-AAD, Acridine Orange, Alexa 488, Alexa 532, Alexa 546, Alexa 568, Alexa 594, Aminonapthalene, Benzoxadiazole, BODIPY 493/504, BODIPY 505/515, BODIPY 576/589, BODIPY FL, BODIPY TMR, BODIPY TR, Carboxytetramethylrhodamine, Cascade Blue, a Coumarin, Cy2, CY3, CY5, CY9, Dansyl Chloride, DAPI, Eosin, Erythrosin, Ethidium Homodimer II, Ethidium Bromide, Fluorescamine, Fluorescein, FTC, GFP (yellow shifted mutants T203Y, T203F, S65G/S72A), Hoechst 33242, Hoechst 33258, IAEDANS, an Indopyras Dye, a Lanthanide Chelate, a Lanthanide Cryptate, Lissamine Rhodamine, Lucifer Yellow, Maleimide, MANT, MQAE, NBD, Oregon Green 488, Oregon Green 514, Oregon Green 500, Phycoerythrin, a Porphyrin, Propidium Iodide, Pyrene, Pyrene Butyrate, Pyrene Maleimide, Pyridyloxazole, Rhodamine 123, Rhodamine 6G, Rhodamine Green, SPQ, Texas Red, TMRM, TOTO-1, TRITC, YOYO-1, vitamin B12, flavin-adenine dinucleotide, and nicotinamide-adenine dinucleotide. 12. The method of claim 1, wherein said fluorescence-labeled ligand comprises a fluorochrome having a fluorescence emission spectra lifetime greater than about 3 nanoseconds. 13. The method of claim 12, wherein said fluorescence-labeled ligand comprises a fluorochrome having a fluorescence emission spectra lifetime greater than about 4 nanoseconds. 14. The method of claim 13, wherein said fluorescence-labeled ligand comprises a fluorochrome having a fluorescence emission spectra lifetime greater than about 5 nanoseconds.

Details for Patent 8,114,582

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2023-11-05